# EDGAR Filing Document

**Accession Number:** 0002035832
**File Stem:** 0001193125-26-013469
**Filing Date:** 2026-1
**Character Count:** 12184
**Document Hash:** a2596ac04a4ecd94754407775669e63c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-013469.hdr.sgml**: 20260115

**ACCESSION NUMBER**: 0001193125-26-013469

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260115

**DATE AS OF CHANGE**: 20260115

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aktis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0002035832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852584233
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95421
- **FILM NUMBER:** 26534616

**BUSINESS ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 978-237-4380

**MAIL ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ELI LILLY & Co
- **CENTRAL INDEX KEY:** 0000059478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 350470950
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** LILLY CORPORATE CTR
- **STREET 2:** DROP CODE 1094
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285
- **BUSINESS PHONE:** 3172762000

**MAIL ADDRESS:**
- **STREET 1:** LILLY CORPORATE CENTER
- **STREET 2:** DROP CODE 1094
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LILLY ELI & CO
- **DATE OF NAME CHANGE:** 19941024

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_a.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Aktis Oncology, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**00973N102**

*(CUSIP Number)*

**Anat Hakim**<br>Lilly Corporate Center<br>Indianapolis IN 46285<br>(317) 276-2000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/12/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00973N102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Eli Lilly and Company** | Name of reporting person<br>**Eli Lilly and Company** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**INDIANA** | Citizenship or place of organization<br>**INDIANA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**6344114.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**6344114.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6344114.00** | Aggregate amount beneficially owned by each reporting person<br>**6344114.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.9%** | Percent of class represented by amount in Row (11)<br>**11.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** This percentage is calculated based upon 53,296,950 outstanding shares of Common Stock of the Issuer following the consummation of its initial public offering as described in its Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended, on January 9, 2026, after giving effect to the full exercise of the underwriters' option to purchase an additional 2,647,500 shares of Common Stock, as disclosed in the press release issued by the Issuer on January 13, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
Aktis Oncology, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
17 DRYDOCK AVENUE, SUITE 17-401, BOSTON, MA, 02210

**Item 4. Purpose of Transaction**

The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis. Except as set forth herein, the Reporting Person does not currently have any specific plan or proposal to acquire or dispose of Common Stock of the Issuer or any securities exercisable for or convertible into Common Stock of the Issuer, but the Reporting Person, consistent with its investment purpose, may at any time and from time to time directly or indirectly acquire additional or all shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer, or dispose of any or all of its shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer. The Reporting Person's determination to make any such acquisitions or dispositions, in each such case, will depend upon a variety of factors, including, but not limited to, an ongoing evaluation of its investment in such securities, applicable legal and/or contractual restrictions, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Person and/or other investment considerations. In addition, in connection with the foregoing, the Reporting Person may engage in hedging or other transactions with respect to securities of the Issuer, including but not limited to, swaps and other derivative instruments.

As part of its ongoing evaluation of its investment in the Issuer, the Reporting Person expects to engage in discussions with directors, officers, members of management and representatives of the Issuer, and may engage in discussions with stockholders, security holders or other interested parties, from time to time covering a range of topics concerning its investment and the Issuer, including operational, financial and strategic initiatives. Furthermore, without limitation, the Reporting Person may also evaluate and discuss other ideas, that if effected, may relate to, or result in, any other matter listed in Items 4(a)-(j) of Schedule 13D. To facilitate its consideration of such matters, the Reporting Person may retain consultants and advisors and may enter into discussions with potential sources of capital and other third parties. The Reporting Person may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements. The Reporting Person will likely take some or all of the foregoing steps at preliminary stages in its consideration of various possible courses of action before forming any intention to pursue any specific plan or proposal.

Other than as described above, the Reporting Person reports that neither it nor, to its knowledge, any of the other persons listed on Schedule A attached to this Schedule 13D, currently has any specific plan or proposal which relates to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although the Reporting Person may, at any time and from time to time, review or reconsider its position and/or change its purpose and/or formulate plans or proposals with respect thereto.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person directly holds an aggregate of 6,344,114 shares of Common Stock, representing approximately 11.9% of the issued and outstanding shares of Common Stock of the Issuer. Ownership percentages set forth in this Schedule 13D are based upon a total of 53,296,950 shares of Common Stock outstanding as of January 14, 2026, following the consummation of the Issuer's IPO as described in its Prospectus filed under Rule 424(b)(4) of the Securities Act of 1933, as amended, on January 9, 2026, after giving effect to the full exercise of the underwriters' option to purchase an additional 2,647,500 shares of Common Stock, as disclosed in the press release issued by the Issuer on January 13, 2026.

**(b)**
The information included in part (a) of Item 5 above is incorporated by reference herein.

**(c)**
Other than as described in Item 3, the Reporting Person has not purchased or sold any shares of the Issuer's common stock during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Investors' Rights Agreement

The Reporting Person and certain other stockholders of the Issuer have entered into a Third Amended and Restated Investors' Rights Agreement with the Issuer (the "Investors' Rights Agreement"), which provides such stockholders with customary registration rights under the Securities Act of 1933, including demand registration rights, piggyback registration rights and shelf registration rights. The Issuer is required to pay all expenses, subject to certain conditions and exceptions, relating to the exercise of such registration rights. The Investors' Rights Agreement also contains customary cross-indemnification provisions. The Reporting Person's registration rights will terminate upon the earlier of (i) the closing of certain deemed liquidation events, as defined in the Issuer's certificate of incorporation, (ii) when the Reporting Person beneficially owns (together with its "affiliates," as defined in Rule 144 under the Securities Act of 1933, as amended) less than 1% of the Issuer's outstanding capital stock and is able to sell all of its shares pursuant to Rule 144 or another similar exemption during a three-month period without registration and (iii) the third anniversary of the IPO.

Lock-Up Agreement

The Reporting Person has entered into a lock-up agreement pursuant to which the Reporting Person has agreed not to, among other things and subject to various exceptions, sell or transfer Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for 180 days after January 8, 2026 without first obtaining the prior written consent of J.P. Morgan Securities LLC, BofA Securities, Inc., Leerink Partners LLC and TD Securities (USA) LLC on behalf of the underwriters.

The foregoing descriptions of the Investors' Rights Agreement and the lock-up agreement do not purport to be complete and are qualified in their entirety by reference to the Investors' Rights Agreement and the form of lock-up agreement, listed as Exhibit 2.1 and Exhibit 2.2 hereto, respectively, and incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Eli Lilly and Company

**Signature:** /s/ Christopher Anderson

**Name/Title:** Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Corporate Secretary

**Date:** 01/15/2026